Coulter Partners places CSO at Alltrna
LONDON, UK and BOSTON, MA - September 18, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alltrna and is pleased to announce the placement of David (Dave) Hava, Ph.D., as Chief Scientific Officer (CSO).
Alltrna, a Flagship Pioneering company, is unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease.
With nearly two decades of drug development experience, Dr. Hava has led multidisciplinary teams that advanced multiple first-in-class modalities from discovery to Phase 3 trials, forged strategic collaborations with global biopharma leaders, and secured substantial capital to fuel innovation.
“We truly appreciated Coulter's partnership on this and other projects,” said Michelle C. Werner, Chief Executive Officer of Alltrna. They continued:
Dave combines deep scientific rigor with a proven ability to translate breakthrough science into transformative medicines. His track record of building high-performing R&D organizations and scaling novel therapeutic modalities will be instrumental as we expand and prioritize our pipeline of tRNA medicines.
----
Dr. David Hava, Chief Scientific Officer at Alltrna
Dr. Hava is an accomplished biotech entrepreneur with nearly two decades of experience advancing innovative therapies across rare, inflammatory, metabolic, respiratory, and oncologic diseases. He brings deep expertise in drug delivery and complex product development, with a proven track record of translating novel science into clinical-stage programs. Dr. Hava most recently served as Entrepreneur-in-Residence at Mass General Brigham Ventures (MGBV), where he was a founding CEO of a stealth startup and provided scientific expertise and leadership for new company formation efforts and existing companies in the MGBV portfolio. Previously, he was CSO and Head of Research and Development at Synlogic, where he led the discovery and development of first-in-class engineered bacterial medicines and advanced a drug candidate for the treatment of phenylketonuria from nomination to Phase 2 and subsequently launched a global Phase 3 study. Earlier in his career, he held CSO roles at Pulmatrix Inc. and Metera Pharmaceuticals, companies advancing inhaled small molecule therapies for serious respiratory diseases.
Dr. Hava received his Ph.D. in molecular biology and microbiology from Tufts University and completed postdoctoral training at Brigham and Women’s Hospital and Harvard Medical School. He is an inventor on multiple patents and author of more than 40 peer-reviewed publications.
